GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Editas Medicine Inc (NAS:EDIT) » Definitions » Institutional Ownership

EDIT (Editas Medicine) Institutional Ownership : 76.25% (As of Dec. 14, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Editas Medicine Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Editas Medicine's institutional ownership is 76.25%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Editas Medicine's Insider Ownership is 3.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Editas Medicine's Float Percentage Of Total Shares Outstanding is 78.95%.


Editas Medicine Institutional Ownership Historical Data

The historical data trend for Editas Medicine's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Editas Medicine Institutional Ownership Chart

Editas Medicine Historical Data

The historical data trend for Editas Medicine can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 41.67 47.09 46.77 46.27 38.78 39.49 39.32 34.58 34.82 34.91

Editas Medicine Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Editas Medicine Business Description

Traded in Other Exchanges
Address
11 Hurley Street, Cambridge, MA, USA, 02141
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Executives
Baisong Mei officer: SVP, CHIEF MEDICAL OFFICER C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Gilmore Neil O'neill director, officer: CEO 215 FIRST STREET, CAMBRIDGE MA 02142
Linda Burkly officer: EVP, CHIEF SCIENTIFIC OFFICER 1 MAIN STREET, CAMBRIDGE MA 02142
Erick Lucera officer: EVP, CHIEF FINANCIAL OFFICER 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bruce Eaton officer: EVP, Chief Business Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Michelle Robertson officer: Chief Financial Officer C/O MOMENTA PHARMACEUTICALS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Elliott M. Levy director C/O OMEGA THERAPEUTICS, INC., 20 ACORN PARK D, CAMBRIDGE MA 02140
Mark S Shearman officer: EVP, Chief Scientific Officer C/O APPLIED GENETIC TECHNOLOGIES CORP, 11801 RESEARCH DRIVE, SUITE D, ALACHUA FL 32615
Lisa Anne Michaels officer: EVP/Chief Medical Officer C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142
Bernadette Connaughton director C/O VISTERRA, INC., ONE KENDALL SQUARE, #B3301, CAMBRIDGE MA 02139
James C Mullen director 940 WINTER STREET, PERKINELMER, INC LEGAL DEPARTMENT, WALTHAM MA 02451
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Cynthia Collins director 65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Meeta Chatterjee director C/O EDITAS MEDICINE, INC., 1 MAIN STREET, CAMBRIDGE MA 02142